CANCER AND LEUKEMIA GROUP B
CANCER AND LEUKEMIA GROUP B
批准号:
6172196
负责人:
Thomas C. Shea
金额:
$11.5万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-06-01 至 2003-03-31
关键词:
AIDS related neoplasm /cancer aging antineoplastics bone marrow transplantation breast neoplasms cancer prevention cancer registry /resource carmustine chemoprevention cis platinum compound clinical research clinical trials combination cancer therapy combination chemotherapy cooperative study cyclophosphamide doxorubicin drug resistance finasteride fluorouracil gastrointestinal neoplasms health care cost /financing hormone therapy human genetic material tag human subject human therapy evaluation interleukin 2 leucovorin leukemia lymphoma melanoma neoplasm /cancer chemotherapy neoplasm /cancer diagnosis neoplasm /cancer epidemiology neoplasm /cancer genetics neoplasm /cancer immunotherapy neoplasm /cancer radiation therapy neoplasm /cancer surgery neoplasm /cancer vaccine oncology nursing paclitaxel pathology prostate neoplasms psychology quality of life respiratory neoplasm tamoxifen tissue resource /registry weight loss
中文摘要
描述(改编自申请人的摘要):本申请
代表CALGB机构赠款的第二次竞争性更新
位于查佩尔山的北卡罗来纳州大学(UNC-CH)提交的意见书,
其附属公司。 UNC-CH自1986年以来一直是CALGB的成员。 我们有
从1992年至1996年,每年平均累积120个案件,
增加七个新附属机构,包括位于的亚拉巴马大学
伯明翰在过去的三年里,预计在150多个
未来几年。 大约60%的总应计费用来自我们的
附属机构。 我们的整体少数股权应计比例仍为2.5%,
组的平均值。 这导致我们获得了少数人的支持,
1997年集团的倡议计划赠款和1998年的申请
在即将到来的赠款期间继续资助少数民族倡议计划
周期 我们的多学科努力和重大贡献
手术研究也使我们成为12个
大卫博士在手术补助金资助下的机构
Sugarbaker是首席研究员。 此外,我们的机构
展示了广泛的领导参与小组在辐射
肿瘤学、白血病、淋巴瘤、乳腺癌、移植、相关科学,
流行病学,病理学,癌症预防和控制,以及GI癌症,
我们附属医学院的少数民族CCOP研究基地
弗吉尼亚州。 在上一个供资周期,我们有以下区别:
设有两名委员会主席、四名委员会副主席、一个工作组
主席,28名核心和执行委员会成员,12名礼宾负责人
调查员或共同调查员和两名董事会成员。
这一直排在前两个或三个机构,
CALGB集团内部评分系统的“领导力”类别。 我们
计划通过保持活跃的
分子流行病学参考实验室和一个独立资助的
生殖系DNA库的核心设施,用于患者的遗传研究
乳腺癌和其他实体瘤。 虽然刘博士的
林恩女士说,离开国家癌症研究所对她和整个团体来说都是一个损失。
Dressler在进行相关研究方面拥有丰富的经验,
合作小组,并将能够继续开展工作,
是她和刘医生发起的 我们认为,这一申请反映了
联合国儿童基金会调查员对以下方面作出的日益重要的贡献:
领导力、科学和服务方面的团队以及我们对
通过增加主要联营公司增加应计项目,同时维持
严格的数据提交质量控制。 我们恭敬地提出,
这一应用程序既证明了该机构的价值,
联合国人居中心及其附属机构将在
未来
英文摘要
DESCRIPTION (adapted from the applicant's abstract): This application
represents the second competitive renewal of the CALGB institutional grant
submission from the University of North Carolina at Chapel Hill (UNC-CH) and
its affiliates. UNC-CH has been a member of CALGB since 1986. We have
maintained an average annual accrual of 120 cases from 1992-1996 and with
the addition of seven new affiliates, including the University of Alabama at
Birmingham in the last three years, are projecting more than 150 in the
coming years. Approximately 60 percent of our total accrual is from our
affiliates. Our overall minority accrual of percent remains at two one-half
times the group average. This has resulted in our obtaining a Minority
Initiative Program Grant from the group for 1997 and an application from UNC
for continued Minority Initiative Program funding during the coming Grant
cycle. Our multidisciplinary efforts and significant contributions to
surgical studies in the group has also resulted in our being one of 12 Group
Institutions with funding from the Surgery Grant on which Dr. David
Sugarbaker is the Principal Investigator. Moreover, our institution has
demonstrated broad leadership participation in the group in Radiation
Oncology, Leukemia, Lymphoma, Breast, Transplant, Correlative Sciences,
Epidemiology, Pathology, Cancer Prevention and Control, and GI Cancer and is
the research base for a Minority CCOP at our affiliate, the Medical College
of Virginia. During the past funding cycle, we have had the distinction of
having two committee chairs, four committee vice-chairs, one working group
chair, 28 Core and Executive Committee members, 12 protocol principal
investigators or co-investigators and two members of the Board of Directors.
This has ranked UNC consistently among the top two or three institutions in
the "leadership" category of the internal CALGB Group scoring system. We
plan to continue direct service to the group by maintaining an active
reference laboratory in molecular epidemiology and an independently funded
core facility for banking of germ line DNA for genetic studies in patients
with breast cancer and other solid tumors. Although Dr. Edison Liu's
departure to the NCI is a loss for UNC and the entire group, Ms. Lynn
Dressler has extensive experience in performing correlative studies within
the Cooperative Groups and will be more than able to continue the work which
she and Dr. Liu had initiated. We believe that this application reflects
the growing and crucial contribution that UNC-CH investigators provide to
the group in leadership, science, and service as well as our commitment to
increase accrual through the addition of major affiliates while maintaining
rigorous quality control of data submission. We respectfully submit that
this application demonstrates both the value of this institution to the
group and the contributions that UNC-CH and its affiliates will provide in
the future.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM
-
批准号:7100785
-
项目类别:
-
资助金额:$8.15万
-
财政年份:2004
-
负责人:Thomas C. Shea
-
依托单位:
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER
-
批准号:6566079
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2001
-
负责人:Thomas C. Shea
-
依托单位:
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS
-
批准号:6566059
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2001
-
负责人:Thomas C. Shea
-
依托单位:
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS
-
批准号:6423230
-
项目类别:
-
资助金额:$29.46万
-
财政年份:2000
-
负责人:Thomas C. Shea
-
依托单位:
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS
-
批准号:6504207
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:Thomas C. Shea
-
依托单位:
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER
-
批准号:6504227
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:Thomas C. Shea
-
依托单位:
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER
-
批准号:6423250
-
项目类别:
-
资助金额:$29.46万
-
财政年份:2000
-
负责人:Thomas C. Shea
-
依托单位:
HIGH DOSE CARBOPLATIN AND PACLITAXEL WITH G-CSF IN NON-SMALL CELL LUNG CANCER
-
批准号:6113933
-
项目类别:
-
资助金额:$1.58万
-
财政年份:1998
-
负责人:Thomas C. Shea
-
依托单位:
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS
-
批准号:6263850
-
项目类别:
-
资助金额:$0.02万
-
财政年份:1998
-
负责人:Thomas C. Shea
-
依托单位:
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER
-
批准号:6263870
-
项目类别:
-
资助金额:$0.02万
-
财政年份:1998
-
负责人:Thomas C. Shea
-
依托单位:
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS
-
批准号:6297218
-
项目类别:
-
资助金额:$0.02万
-
财政年份:1998
-
负责人:Thomas C. Shea
-
依托单位:
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER
-
批准号:6297238
-
项目类别:
-
资助金额:$0.02万
-
财政年份:1998
-
负责人:Thomas C. Shea
-
依托单位:
BLOOD PROGENITOR CELL MOBILIZATION BY R-METHUSCF & R-METHUG-CSF IN BREAST CANCER
-
批准号:6244976
-
项目类别:
-
资助金额:$1.34万
-
财政年份:1997
-
负责人:Thomas C. Shea
-
依托单位:
HIGH DOSE CARBOPLATIN AND PACLITAXEL WITH G-CSF IN NON-SMALL CELL LUNG CANCER
-
批准号:6275168
-
项目类别:
-
资助金额:$1.58万
-
财政年份:1997
-
负责人:Thomas C. Shea
-
依托单位:
PERIPHERAL BLOOD STEM CELLS AND HIGH DOSE CHEMOTHERAPY
-
批准号:3509642
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1992
-
负责人:Thomas C. Shea
-
依托单位:
CANCER AND LEUKEMIA GROUP B
-
批准号:2599516
-
项目类别:
-
资助金额:$19.36万
-
财政年份:1991
-
负责人:Thomas C. Shea
-
依托单位:
CANCER AND LEUKEMIA GROUP B
-
批准号:2894766
-
项目类别:
-
资助金额:$11.96万
-
财政年份:1991
-
负责人:Thomas C. Shea
-
依托单位:
Cancer and Leukemia Group B
-
批准号:8449714
-
项目类别:
-
资助金额:$14.5万
-
财政年份:1991
-
负责人:Thomas C. Shea
-
依托单位:
CANCER AND LEUKEMIA GROUP B
-
批准号:2092635
-
项目类别:
-
资助金额:$17.02万
-
财政年份:1991
-
负责人:Thomas C. Shea
-
依托单位:
Cancer and Leukemia Group B
-
批准号:6892330
-
项目类别:
-
资助金额:$12.78万
-
财政年份:1991
-
负责人:Thomas C. Shea
-
依托单位:
海外基金